Clinical trials: Endocrine System Disorder
Diabetes Mellitus
Metabolic Effect of Insulin Aspart and Human Insulin in Different Doses
The metabolic effect of three different doses of insulin aspart and human insulin are investigated with the euglycaemic glucose clamp technique.
- Trial name
- NCT00513643
- Testing
- insulin aspart, human regular insulin
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Cancer
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
This study will examine the efficacy and safety of lapatinib in patients with ErbB2 positive ovarian, gastric/esophageal adenocarcinoma, uterine serous papillary, or bladder cancers.
- Trial name
- NCT00447226
- Where
- 20 sites in United States
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder
A Study of AZD4901 in Females With Polycystic Ovary Syndrome
To assess the effects of AZD4901 when given in multiple doses to females with Polycystic Ovary Syndrome
- Trial name
- NCT01872078
- Testing
- AZD4901 (oral)
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Bangladesh
This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control, complications in diabetic subjects in Asia.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare Asia (NCT00839878)
- Testing
- No treatment given
- Where
- Bangladesh
- Volunteers
- 2,092 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)
The purpose of this study is to assess the effects of administration of canagliflozin 100 mg and 300 mg, compared with placebo as an addition to insulin therapy for the treatment of Type 1 Diabetes Mellitus (T1DM).
- Trial name
- NCT02139943
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg
- Where
- 53 sites in United States, Canada
- Volunteers
- 352 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change.
- Trial name
- LixiLan-G (NCT02787551)
- Testing
- Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide
- Where
- 124 sites in United States, Canada and 7 more
- Volunteers
- 514 people
- Sponsor
- Sanofi
Hyponatremia, Dilutional Hyponatremia
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
The purpose of this study is to determine if hospitalized patients with symptomatic hyponatremia treated with tolvaptan are in the hospital for less time than patients treated with fluid restriction.
- Conditions
- Hyponatremia, Dilutional Hyponatremia, Inappropriate ADH Syndrome
- Trial name
- SALACIA (NCT01227512)
- Testing
- tolvaptan, Fluid Restriction
- Where
- 56 sites in United States
- Volunteers
- 124 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Ovarian Neoplasms
Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.
- Trial name
- NCT00038428
- Testing
- TLK286
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Telik
Diabetic Foot Ulcers
Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers
The purpose of this study is to determine whether AppliGel-G (Gentamicin topical gel) plus oral Ciprofloxacin / Doxycycline are safe and effective in the treatment of mild to moderately infected foot ulcers in diabetic patients.
- Trial name
- NCT02036528
- Testing
- Gentamicin Topical Gel, Ciprofloxacin, Doxycycline
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Royer Biomedical, Inc.
Pancreatic Cancer
A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
This trial was a single-arm, open-label design to evaluate the efficacy and safety of "TQB2916+ gemcitabine + albumin-paclitaxel" as the first-line treatment for metastatic pancreatic cancer.
- Trial name
- NCT06962267
- Testing
- TQB2916 Injection, Chemotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Insulin Dependent Diabetes, Non Insulin Dependent Diabetes
Evaluation and Comparison of Noninvasive Blood Glucose Concentrations
Comparison of noninvasive glucose measurement performance versus standard invasive reference measurements.
- Conditions
- Insulin Dependent Diabetes, Non Insulin Dependent Diabetes, Gestational Diabetes
- Trial name
- NCT01745900
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- VeraLight, Inc.
Hypertension, Ischemic Heart Disease
Vibrometer Based Pulse Wave Analysis for Arterial Stiffness and Ischemic Heart Disease Risk Assessment
This clinical investigation will evaluate a novel contactless technology for assessing arterial stiffness and explore its potential in assessment of risk for and development of cardiovascular disease.
- Conditions
- Hypertension, Ischemic Heart Disease, Valvular Heart Disease, Heart Failure
- Trial name
- NCT06984211
- Where
- 3 sites in Sweden
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- HJN Sverige AB/Neko Health
Diabetes Mellitus, Dyslipidemias
Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.
The purpose of this study is to compare pioglitazone and metformin combination therapy, twice daily (BID), to glimepiride and metformin combination therapy for treating diabetic subjects with dyslipidemia.
- Trial name
- NCT00770653
- Testing
- Pioglitazone and Metformin, Glimepiride and Metformin
- Where
- 64 sites in Germany
- Volunteers
- 305 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy Volunteers
This study will assess safety and tolerability when taking GSK189075 at doses that are likely to be higher than the expected prescribed doses.
- Trial name
- NCT00501930
- Testing
- GSK189075
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus Type 1
Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal
The addition of BioChaperone to already marketed prandial insulin analogue accelerates the onset and shorten the duration of action of insulin lispro due to facilitation of the absorption of the insulin after subcutaneous…
- Trial name
- NCT02344992
- Testing
- BioChaperone insulin lispro, Humalog®
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Adocia
Diabetes Mellitus
Project BLOOM Regulatory Clinical Evaluation - System Accuracy, User Performance and System Use Evaluation
Clinical Evaluation including System Accuracy, User Performance, System Use, Instructions for Use and Marketing Claims Evaluation.
- Trial name
- NCT02767336
- Testing
- Blood Glucose Monitoring System.
- Where
- 4 sites in United Kingdom
- Volunteers
- 174 people
- Sponsor
- LifeScan
Diabetic Foot Ulcer
TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers
Patients will be randomized to receive TheraGauze alone or with Regranex to treat diabetic foot ulcer condition. The purpose of the study is provide the sponsor with pilot information regarding the ability of TheraGauze to…
- Trial name
- NCT00389636
- Testing
- TheraGauze, Regranex
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Solsys Medical LLC
Hypertension, Diabetes
A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients
To evaluate the blood pressure lowering effect and safety of aliskiren used in combination with valsartan/hydrochlorothiazide in diabetic patients with essential hypertension, not adequately responsive to the combination of…
- Trial name
- NCT00219102
- Testing
- aliskiren
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 336 people
- Sponsor
- Novartis
Diabetes Mellitus
Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes
The purpose of this study is to evaluate the safety and efficacy of alogliptin as an add-on to a rapid-acting insulin secretagogue (medicine that stimulates insulin release) in type 2 diabetic patients with inadequate blood…
- Trial name
- NCT01456130
- Testing
- Alogliptin, Rapid-acting insulin secretagogue
- Where
- 14 sites in Japan
- Volunteers
- 67 people
- Sponsor
- Takeda
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.